Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.

Barsheshet A, Goldenberg I, Moss AJ, Huang DT, Zareba W, McNitt S, Klein HU, Guetta V.

J Cardiovasc Electrophysiol. 2011 Nov;22(11):1237-42. doi: 10.1111/j.1540-8167.2011.02096.x. Epub 2011 May 26.

PMID:
21615813
2.

Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.

Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, Wilber DJ, Klein HU; MADIT-II Investigators.

J Am Coll Cardiol. 2006 May 2;47(9):1811-7. Epub 2006 Apr 17.

3.

Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. "Routine Practice" data from the SEARCH MI registry.

Boriani G, Botto G, Lunati M, Proclemer A, Schmidt B, Erdogan A, Rauhe W, Biffi M, Santi E, Becker D, Messier M, Santini M.

BMC Cardiovasc Disord. 2012 Sep 11;12:72. doi: 10.1186/1471-2261-12-72.

4.

Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.

Forleo GB, Della Rocca DG, Papavasileiou LP, Panattoni G, Sergi D, Duro L, Mahfouz K, Magliano G, Santini L, Romeo F.

J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):779-84. doi: 10.2459/JCM.0b013e32834ae458.

PMID:
21941203
5.

Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.

Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA, Reiber JH, Zeppenfeld K, Lamb HJ, de Roos A, Schalij MJ, Bax JJ.

Circ Cardiovasc Imaging. 2009 May;2(3):183-90. doi: 10.1161/CIRCIMAGING.108.826529. Epub 2009 Mar 23.

6.

Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.

Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W; Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II.

Circulation. 2010 Sep 28;122(13):1265-71. doi: 10.1161/CIRCULATIONAHA.110.940148. Epub 2010 Sep 13.

8.

Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.

Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I; Multicenter Automatic Defibrillator Implantation Trial-II Investigators.

Am J Cardiol. 2010 Mar 1;105(5):581-6. doi: 10.1016/j.amjcard.2009.10.041. Epub 2010 Jan 22.

PMID:
20185000
9.

Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.

Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I.

J Am Coll Cardiol. 2012 Jun 5;59(23):2075-9. doi: 10.1016/j.jacc.2012.02.036.

10.

Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):785-92. doi: 10.1161/CIRCEP.114.001623. Epub 2014 Aug 18.

11.

Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.

Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2007 Feb;18(2):181-4.

PMID:
17338766
12.

Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.

Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, Spuller K, Strasak A, Pachinger O, Haegeli LM, Duru F, Hintringer F.

Clin Cardiol. 2011 Jul;34(7):433-6. doi: 10.1002/clc.20910. Epub 2011 Jun 15.

13.

Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.

Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T.

Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):16-24. doi: 10.1161/CIRCOUTCOMES.108.807123. Epub 2009 Jan 6.

14.

Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery disease.

Blumer J, Wolber T, Hellermann J, Holzmeister J, Binggeli C, Duru F, Brunckhorst C.

Int Heart J. 2009 May;50(3):313-21.

15.

Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis.

Piccini JP, Al-Khatib SM, Myers ER, Anstrom KJ, Buxton AE, Peterson ED, Sanders GD.

J Cardiovasc Electrophysiol. 2010 Jul;21(7):791-8. doi: 10.1111/j.1540-8167.2009.01696.x. Epub 2010 Feb 1.

PMID:
20132397
16.

Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML; MADIT-II Investigators.

J Am Coll Cardiol. 2008 Jan 22;51(3):288-96. doi: 10.1016/j.jacc.2007.08.058.

17.

Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798. Epub 2012 Jun 8.

18.

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators.

N Engl J Med. 2004 Dec 9;351(24):2481-8.

19.

Fragmented QRS and mortality risk in patients with left ventricular dysfunction.

Cheema A, Khalid A, Wimmer A, Bartone C, Chow T, Spertus JA, Chan PS.

Circ Arrhythm Electrophysiol. 2010 Aug;3(4):339-44. doi: 10.1161/CIRCEP.110.940478. Epub 2010 May 28.

20.

Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.

Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1.

PMID:
20132378

Supplemental Content

Support Center